Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Current Deferred Revenue: 2010-2018

Historic Current Deferred Revenue for Heron Therapeutics (HRTX) over the last 2 years, with Dec 2018 value amounting to $14.0 million.

  • Heron Therapeutics' Current Deferred Revenue rose 407.06% to $14.0 million in Q4 2018 from the same period last year, while for Dec 2018 it was $14.0 million, marking a year-over-year increase of 407.06%. This contributed to the annual value of $14.0 million for FY2018, which is 407.06% up from last year.
  • Per Heron Therapeutics' latest filing, its Current Deferred Revenue stood at $14.0 million for Q4 2018, which was up 33.12% from $10.5 million recorded in Q3 2018.
  • Heron Therapeutics' Current Deferred Revenue's 5-year high stood at $14.0 million during Q4 2018, with a 5-year trough of $1.1 million in Q4 2016.
  • In the last 3 years, Heron Therapeutics' Current Deferred Revenue had a median value of $5.2 million in 2017 and averaged $6.2 million.
  • The largest annual percentage gain for Heron Therapeutics' Current Deferred Revenue in the last 5 years was 407.06% (2018), contrasted with its biggest fall of 55.21% (2018).
  • Quarterly analysis of 3 years shows Heron Therapeutics' Current Deferred Revenue stood at $1.1 million in 2016, then soared by 151.41% to $2.8 million in 2017, then soared by 407.06% to $14.0 million in 2018.
  • Its Current Deferred Revenue stands at $14.0 million for Q4 2018, versus $10.5 million for Q3 2018 and $9.4 million for Q2 2018.